Manufacturing segment will grow fast over the next decade: Syngene CEO

In a Q&A, Jonathan Hunt talks about his company's capex plans and strategic initiatives going forward

Biotech contract research firm Syngene saw its revenue from operations grow 10 per cent to Rs 641 crore in Q3 on a year-on-year basis, while profit before tax also grew 10 per cent to Rs 128 crore. Syngene CEO and MD Jonathan Hunt spoke to Sohini Das and Deepsekhar Choudhury about the company’s capex plans and strategic initiatives going forward. Edited excerpts:

What kind of capex would you have to undertake for the Amgen project?

The Amgen capex is already covered in our multi-year capex plan. It is not a transformational amount or a trend break on the amount of